[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100520661":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":20,"locations":30,"responsibleParty":46,"collaborators":19,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":19,"enrollmentInfo":58,"targetDuration":19,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":19,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Jules Bordet Institute","OTHER",[8],{"label":9,"type":10,"description":9,"interventionNames":11},"Patients with progressive metastatic TNBC and presenting measurable disease on 18F-FDG PET\u002FCT","EXPERIMENTAL",[12],"Diagnostic Test: Ga-PSMA PET\u002FCT",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"DIAGNOSTIC_TEST","Ga-PSMA PET\u002FCT","Patient undergo Ga-PSMA PET\u002FCT prior to the start of the new drug treatment",[9],null,[21,26],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Géraldine Gebhart, MD","CONTACT","025413095","geraldine.gebhart@hubruxelles.be",{"name":27,"role":23,"phone":28,"phoneExt":19,"email":29},"Loubna Taraji, Ms","025413781","loubna.taraji@hubruxelles.be",[31],{"facility":32,"status":33,"city":34,"state":19,"zip":19,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Institut Jules Bordet","RECRUITING","Brussels","Belgium","BE",{"type":38,"coordinates":39},"Point",[40,41],4.34878,50.85045,{"lat":41,"lon":40},[44],{"name":45,"role":23,"phone":19,"phoneExt":19,"email":29},"Loubna Taraji Schiltz",{"type":47,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100520661","phase-2-psma-petct-to-assess-the-expression-of-specific-membrane-antigen-psma-in-patients-with-progressive-triple-negative-breast-cancer-100520661",false,"NCT06059469","PSMA-PET\u002FCT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer.","PRISMA: A Single-centre, Prospective Phase II Imaging Study Using PSMA-PET\u002FCT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer.","PRISMA","Inclusion Criteria:\n\n* Written informed consent in accordance with institutional guidelines and obtained prior to any study procedure\n* Women with ≥ 18 years-old\n* Eastern Cooperative Oncology Group Performance Status of 0 to 2\n* Confirmed diagnosis of progressive metastatic TNBC and presenting measurable disease on 18F-FDG PET\u002FCT (performed within 2 weeks) or Brain MRI in case of progressive brain metastases (performed within 4 weeks) prior to PSMA PET\u002FCT.\n* Radiolabelled PSMA PET\u002FCT has to be performed before the next treatment line initiation\n\nExclusion Criteria:\n\n* Pregnant or lactating patients\n* Other active neoplastic disease\n* Treatment by another molecule that is the object of investigation within 30 days\n* Skin only metastatic disease\n* Patients with a significant medical, neuro-psychiatric, or surgical condition, which, in the investigator's opinion, may interfere with completion of the study","FEMALE","18 Years",{"count":59,"type":60},20,"ESTIMATED","INTERVENTIONAL",[63],"PHASE2","This is a descriptive, prospective, single centre study. This study will assess PSMA expression via the uptake of radiolabelled PSMA-ligand using PET\u002FCT imaging in mTNBC lesions pre-identified on 18F-FDG PET\u002FCT in order to evaluate the feasibility of molecular radionuclide therapy in refractory mTNBC using the Lutetium-177 radiolabelled PSMA.",[66],"TNBC - Triple-Negative Breast Cancer","2025-07-15",{"date":69,"type":70},"2025-07-18","ACTUAL",{"date":72,"type":70},"2022-05-30",{"date":74,"type":60},"2025-12",{"name":5,"class":6},1]